Press Releases

Oragenics, Inc. Files 10K and Provides Company Update

April 1, 2024

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

March 18, 2024

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

March 5, 2024

Oragenics Announces Closing of Public Offering

March 1, 2024

Oragenics Announces Pricing of Public Offering

February 27, 2024

Oragenics Announces Proposed Public Offering

February 27, 2024

Oragenics, Inc. Announces Leadership Transition

February 12, 2024

Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement

February 7, 2024

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

February 5, 2024

Oragenics Announces Termination of At-The-Market Offering Program

January 23, 2024